ROS1 and Alzheimer disease: In period I, 2877 patients (40.5%) in the AD group had at least 1 major druggable sequence variation: EGFR variation (2410 patients), ALK rearrangement (306 patients), ROS1 rearrangement (24 patients), RET rearrangement (23 patients), BRAF V600E variation (28 patients), KRAS G12C variation (85 patients), and NTRK1/2/3 gene fusion (1 patient).